journal article·2025-11-04

Mitochondria-Targeted Dual-Ion Perturbator Amplifies Cuproptosis for Enhanced Melanoma Immunotherapy and Accelerated Postoperative Wound Healing

Han Du, Zhe Li, Shao-Tian Fu, Chang-Jie Yang, Yan-Ze Yin, Zhimin Chen, Chang-Qing Zhao, Han Qiao, Ding-Kun Ji

ACS Nano· Volume 19· Issue 43
Publisher page

Abstract

Melanoma recurrence and full-thickness skin defects severely impair patient recovery and quality of life. There is an urgent need for therapeutic platforms that not only eliminate residual melanoma cells but also accelerate wound healing. Cuproptosis has emerged as a promising anticancer strategy. However, a significant challenge remains in overcoming the adaptive defenses of cancer cells and sensitizing them to cuproptosis. Herein, we explore a mitochondrial-targeted Ca/Cu dual-ion chaos inducer (Mito-chaos) by integrating a mitochondria-targeted curcumin derivative (MitoCur) into a calcium- and copper- co -doped Prussian blue nanoplatform. Mito-chaos exhibits excellent mitochondrial targeting, multienzyme-mimicking catalytic activity, and strong NIR-II photothermal properties. Mito-chaos can precisely deliver Cu 2+ and Ca 2+ ions into mitochondria, disrupting mitochondrial ion homeostasis, inducing calcium overload, and consequently amplifying cuproptosis. Combined with mild NIR-II photothermal treatment, Mito-chaos achieves effective melanoma suppression accompanied by robust antitumor immune activation. Beyond tumor eradication, Mito-chaos significantly enhances skin vascularization and collagen deposition, accelerating postoperative wound healing and reducing wound closure time. This mitochondria-targeted therapeutic platform not only effectively eliminates residual melanoma cells but also promotes tissue regeneration, providing an integrated and effective strategy for melanoma postoperative management. Our study presents a promising paradigm for precisely amplifying subcellular organelle dysfunction to boost cancer cuproptosis therapy and tissue repair.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Autophagy in Disease and Therapy · Nanoplatforms for cancer theranostics · Telomeres, Telomerase, and Senescence

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Molecular Medicine (IMM), Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Renji Hospital

Shanghai Jiao Tong University School of Medicine

Department of Orthopaedic Surgery, Shanghai Ninth People’s Hospital

School of Life Sciences

Shanghai University

Department of Thoracic Surgery, Shanghai Pulmonary Hospital

School of Medicine, Tongji University

Department of Medical Oncology, Shanghai Pulmonary Hospital

Tongji University Medical School Cancer InstituteTongji University School of Medicine

Funding

Natural Science Foundation of Shanghai Municipality · National Key Research and Development Program of China · Fundamental Research Funds for the Central Universities · National Natural Science Foundation of China

References (54)

Show source-provided references
1. 10.1038/s41392-021-00827-610.1038/s41392-021-00827-6 ↗
2. 10.1016/j.addr.2019.11.00210.1016/j.addr.2019.11.002 ↗
3. 10.1016/S1470-2045(21)00065-610.1016/S1470-2045(21)00065-6 ↗
4. 10.1097/CMR.000000000000037910.1097/CMR.0000000000000379 ↗
5. 10.1126/science.abf052910.1126/science.abf0529 ↗
6. 10.1038/s41571-024-00876-010.1038/s41571-024-00876-0 ↗
7. 10.1002/adma.20230824110.1002/adma.202308241 ↗
8. 10.1016/j.xcrm.2023.10126410.1016/j.xcrm.2023.101264 ↗
9. 10.1021/jacs.4c0633810.1021/jacs.4c06338 ↗
10. 10.1002/mco2.72410.1002/mco2.724 ↗
11. 10.1016/j.redox.2024.10326010.1016/j.redox.2024.103260 ↗
12. 10.1038/s41392-020-00342-010.1038/s41392-020-00342-0 ↗
13. 10.1002/adma.20240906610.1002/adma.202409066 ↗
14. 10.1021/acsnano.4c1145510.1021/acsnano.4c11455 ↗
15. 10.1002/adma.20220759310.1002/adma.202207593 ↗
16. 10.1039/D4NR01857E10.1039/D4NR01857E ↗
17. 10.1002/anbr.20240001810.1002/anbr.202400018 ↗
18. 10.34133/bmr.009410.34133/bmr.0094 ↗
19. 10.1038/s41467-023-38796-910.1038/s41467-023-38796-9 ↗
20. 10.1021/acsnano.3c1099410.1021/acsnano.3c10994 ↗
21. 10.1002/adma.20220038910.1002/adma.202200389 ↗
22. 10.1016/j.jcis.2025.13733710.1016/j.jcis.2025.137337 ↗
23. 10.3233/JAD-2004-640310.3233/JAD-2004-6403 ↗
24. 10.1002/anie.20231006110.1002/anie.202310061 ↗
25. 10.1016/j.carbpol.2023.12066810.1016/j.carbpol.2023.120668 ↗
26. 10.1021/acs.jafc.1c0769010.1021/acs.jafc.1c07690 ↗
27. 10.2147/IJN.S25250510.2147/IJN.S252505 ↗
28. 10.1002/advs.20240996710.1002/advs.202409967 ↗
29. 10.1002/adfm.20251053310.1002/adfm.202510533 ↗
30. 10.1002/adma.20200054210.1002/adma.202000542 ↗
31. 10.1016/j.saa.2012.12.04110.1016/j.saa.2012.12.041 ↗
32. 10.1016/j.freeradbiomed.2022.11.02310.1016/j.freeradbiomed.2022.11.023 ↗
33. 10.1002/adfm.20240202210.1002/adfm.202402022 ↗
34. 10.1021/acsnano.4c1444510.1021/acsnano.4c14445 ↗
35. 10.3390/ijms2402147110.3390/ijms24021471 ↗
36. 10.1111/bcp.1397910.1111/bcp.13979 ↗
37. 10.1002/advs.20230998410.1002/advs.202309984 ↗
38. 10.1038/cr.2017.15510.1038/cr.2017.155 ↗
39. 10.1016/j.phymed.2015.11.00510.1016/j.phymed.2015.11.005 ↗
40. 10.1016/j.phymed.2018.04.05810.1016/j.phymed.2018.04.058 ↗
41. 10.1016/j.apsb.2024.05.02910.1016/j.apsb.2024.05.029 ↗
42. 10.3389/fcell.2022.99630710.3389/fcell.2022.996307 ↗
43. 10.1002/adma.20221226710.1002/adma.202212267 ↗
44. 10.1016/j.redox.2021.10210110.1016/j.redox.2021.102101 ↗
45. 10.1021/acsami.3c0939410.1021/acsami.3c09394 ↗
46. 10.3390/antiox1009145110.3390/antiox10091451 ↗
47. 10.1016/j.supflu.2022.10568210.1016/j.supflu.2022.105682 ↗
48. 10.1016/j.biomaterials.2024.12277610.1016/j.biomaterials.2024.122776 ↗
49. 10.1039/C8CS01021H10.1039/C8CS01021H ↗
50. 10.1126/science.211158510.1126/science.2111585 ↗
51. 10.1182/blood.201900297310.1182/blood.2019002973 ↗
52. 10.1038/s41556-021-00822-710.1038/s41556-021-00822-7 ↗
53. 10.1016/j.biomaterials.2020.12019910.1016/j.biomaterials.2020.120199 ↗
54. 10.1038/nprot.2007.3010.1038/nprot.2007.30 ↗